Research Atlas · source screening

Teicoplanin

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

1,565

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Teicoplanin"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Dose-dependent cytotoxicity and modulation of catabolic cytokine expression by teicoplanin in human articular chondrocytes.

   Toxicol In Vitro · 2026 Dec · PMID 42497968 · DOI 10.1016/j.tiv.2026.106289

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. A Decade-Long Nationwide Surveillance of Antimicrobial Resistance in Coagulase-Negative Staphylococci in China (2014-2023) and Characterization of a Rare Teicoplanin-Resistant Staphylococcus haemolyticus.

   J Glob Antimicrob Resist · 2026 Sep 21 · PMID 42767460 · DOI 10.1016/j.jgar.2026.09.009

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Clinical outcomes of teicoplanin for Corynebacterium species bacteremia: A retrospective observational study.

   Eur J Clin Microbiol Infect Dis · 2026 Sep 7 · PMID 42702702 · DOI 10.1007/s10096-026-05665-4

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Complexation of teicoplanin and sulfobutylether-β-cyclodextrin: experimental and theoretical insights into the potential relevance of their molecular interaction to teicoplanin pharmacokinetics.

   Int J Pharm · 2026 Sep 5 · PMID 42471168 · DOI 10.1016/j.ijpharm.2026.127188

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Evaluation of teicoplanin concentrations for loading-dose optimization across BMI categories.

   J Antimicrob Chemother · 2026 Sep 1 · PMID 42773960 · DOI 10.1093/jac/dkag329

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Genome sequence of a methicillin-resistant Staphylococcus epidermidis (MRSE) resistant to dalbavancin and teicoplanin isolated in Italy, 2023.

   J Glob Antimicrob Resist · 2026 Sep · PMID 42167682 · DOI 10.1016/j.jgar.2026.05.006

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Thrice-weekly teicoplanin: an old drug for modern needs. Experience of its use as outpatient parenteral antibiotic therapy (OPAT) at infectious disease unit of Manzoni hospital (Lecco).

   J Chemother · 2026 Sep · PMID 41123236 · DOI 10.1080/1120009X.2025.2575226

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Factors Affecting the Initial Serum Concentration of Teicoplanin in Pediatric Patients: A Single-Center Retrospective Analysis.

   J Pediatric Infect Dis Soc · 2026 Aug 4 · PMID 42570321 · DOI 10.1093/jpids/piag069

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Effect of body composition on initial teicoplanin dosing and optimization of the regimen.

   J Infect Chemother · 2026 Aug · PMID 42269966 · DOI 10.1016/j.jiac.2026.103010

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. Development of a real-world, therapeutic drug monitoring-informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections.

    Int J Clin Pharm · 2026 Aug · PMID 41995939 · DOI 10.1007/s11096-026-02124-0

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. Comparative Effectiveness of Teicoplanin Versus Standard of Care Antibiotics for the Treatment of Gram-Positive Bacteremia: A Seven-Year Retrospective Analysis.

    Open Forum Infect Dis · 2026 Jul · PMID 42534374 · DOI 10.1093/ofid/ofag462

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Fusion Inhibition of Zika Virus Entry by a Teicoplanin Pseudoaglycone Derivative with Broad Antiviral Activity.

    Pharmaceutics · 2026 Jul 17 · PMID 42514955 · DOI 10.3390/pharmaceutics18070879

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Development and in vitro evaluation of teicoplanin PEGylated (TEC-PEGylated) niosomes for antimicrobial and anti-biofilm activity against vancomycin-intermediate Staphylococcus aureus (VISA).

    BMC Biotechnol · 2026 Jul 11 · PMID 42436457 · DOI 10.1186/s12896-026-01201-6

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. From bench to bedside: how dynamic hollow-fibre in vitro infection experiments and mathematical modelling can inform pharmacokinetic/pharmacodynamic targets for teicoplanin.

    Clin Microbiol Infect · 2026 Jun 27 · PMID 42364713 · DOI 10.1016/j.cmi.2026.06.022

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Effects of Tranexamic Acid in Combination with Teicoplanin Against Staphylococcus isolates: Results from an In Vitro Study.

    Int J Mol Sci · 2026 Jun 26 · PMID 42450036 · DOI 10.3390/ijms27135764

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. Is Teicoplanin Resistance Detected By The Automated System In Staphylococcus spp Strains Reliable?

    J Vis Exp · 2026 Jun 5 · PMID 42329822 · DOI 10.3791/69728

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. The Effectiveness of Linezolid and Teicoplanin for Managing Infections After Burn Injuries: A Retrospective Study.

    Health Sci Rep · 2026 Jun · PMID 42255081 · DOI 10.1002/hsr2.72411

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. Development and validation of an artificial intelligence-based model for predicting teicoplanin plasma concentrations in intensive care unit patients with pulmonary infections: a retrospective study.

    Int J Clin Pharm · 2026 Jun · PMID 41849094 · DOI 10.1007/s11096-026-02095-2

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Emergence of Teicoplanin and Linezolid Resistance in Clinical Isolates of Methicillin-Resistant and -Susceptible Staphylococcus aureus.

    Microb Drug Resist · 2026 Jun · PMID 41783908 · DOI 10.1177/10766294261426677

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. "Standard" Is More Than Enough: Therapeutic Drug Monitoring Confirms Early Target Attainment of Teicoplanin Regimens in Pediatric Patients.

    Ther Drug Monit · 2026 May 28 · PMID 42208049 · DOI 10.1097/FTD.0000000000001478

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Defining the unbound target exposure of teicoplanin, Part 2: Dose individualization through population pharmacokinetic modelling.

    Clin Microbiol Infect · 2026 May 22 · PMID 42176739 · DOI 10.1016/j.cmi.2026.05.020

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. Defining the unbound target exposure of teicoplanin, Part 1: Insights from the hollow-fibre system.

    Clin Microbiol Infect · 2026 May 22 · PMID 42176738 · DOI 10.1016/j.cmi.2026.05.019

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Does the teicoplanin skin test predict IgE-mediated hypersensitivity?

    Allergol Select · 2026 · PMID 42205715 · DOI 10.5414/ALX02632E

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Association of vancomycin or teicoplanin gram-positive prophylaxis with infection profile and mortality in ECMO patients: A real-world cohort study.

    Int J Infect Dis · 2026 Apr · PMID 41707951 · DOI 10.1016/j.ijid.2026.108492

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. Corrigendum to "A green and practical strategy for therapeutic drug monitoring of teicoplanin A(2) components in human plasma using functionalized liquid film solvent bar microextraction coupled with high-performance liquid chromatography-ultraviolet detection" [Journal of Chromatography A 1768 (2026) 466673].

    J Chromatogr A · 2026 Mar 29 · PMID 41692609 · DOI 10.1016/j.chroma.2026.466777

    Source metadata only · evidence grade unassigned · scientific conclusions pending review